Vertex Pharmaceuticals debt and dilution—

Borrowings, liquidity, share count and stock-based dilution.

Total debt

USD millions

—

Cash & equivalents

USD millions

$6,143.5M

Net debt

USD millions

—

Debt / equity

—

Debt / assets

—

Net debt / EBITDA

× · TTM

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Debt / FCF

× · TTM

—

Reported borrowing balances are unavailable in the extracted statements for this period.

Interest coverage

× · TTM

—

Current ratio

3.19×

Diluted shares

Million shares

255.2M shares

Basic shares

Million shares

253.7M shares

Share count growth

-1.17%

Share repurchases

USD millions

$469.5M

Quarterly data

Vertex Pharmaceuticals capital history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal period	Ended	Total debtUSD millions	Cash & equivalentsUSD millions	Net debtUSD millions	Debt / equity×	Debt / assets%	Net debt / EBITDA×	Debt / FCF×	Interest coverage×	Current ratio×	Diluted sharesMillion shares	Basic sharesMillion shares	Share count growth%	Share repurchasesUSD millions
FY 2026 Q2	Jun 30, 2026	—	6,143.5	—	—	—	—	—	—	3.19×	255.2	253.7	-1.17%	469.5
FY 2026 Q1	Mar 31, 2026	—	5,492.9	—	—	—	—	—	—	3.02×	256.3	254.1	-1.09%	336.9
FY 2025 Q4	Dec 31, 2025	—	5,084.8	—	—	—	—	—	313.78×	2.9×	256.22	253.62	-1.43%	128.4
FY 2025 Q3	Sep 30, 2025	—	4,939.6	—	—	—	—	—	311.98×	2.36×	257.6	255.6	-0.93%	1,071.1
FY 2025 Q2	Jun 30, 2025	—	4,972.2	—	—	—	—	—	230.79×	2.52×	258.9	256.7	-0.54%	391.8
FY 2025 Q1	Mar 31, 2025	—	4,674.7	—	—	—	—	—	-32×	2.65×	259.5	256.9	-0.5%	426.1
FY 2024 Q4	Dec 31, 2024	—	4,569.6	—	—	—	—	—	-7.61×	2.69×	257.3	257.3	-0.15%	417.9
FY 2024 Q3	Sep 30, 2024	—	5,239.2	—	—	—	—	—	-7.04×	2.47×	261	258	0%	307.7
FY 2024 Q2	Jun 30, 2024	—	4,580.1	—	—	—	—	—	-8.34×	2.52×	258.1	258.1	0.16%	320.3
FY 2024 Q1	Mar 31, 2024	—	9,158	—	—	—	—	—	97.27×	3.5×	261.1	258.2	0.31%	131.2
FY 2023 Q4	Dec 31, 2023	—	10,369.1	—	—	—	—	—	86.89×	3.99×	260.8	257.7	0.28%	149.5
FY 2023 Q3	Sep 30, 2023	—	11,110.2	—	—	—	—	—	—	4.08×	260.6	258	0.58%	117
FY 2023 Q2	Jun 30, 2023	—	10,151.1	—	—	—	—	—	—	4.14×	260.4	257.7	0.7%	28.3
FY 2023 Q1	Mar 31, 2023	—	9,289.9	—	—	—	—	—	—	4.28×	260.3	257.4	0.9%	132.8
FY 2022 Q4	Dec 31, 2022	—	10,504	—	—	—	—	—	78.6×	4.83×	260.29	256.99	0.93%	0
FY 2022 Q3	Sep 30, 2022	—	9,171.5	—	—	—	—	—	—	4.7×	259.5	256.5	-0.53%	0
FY 2022 Q2	Jun 30, 2022	—	8,702.2	—	—	—	—	—	—	4.5×	258.7	255.9	-1.19%	0
FY 2022 Q1	Mar 31, 2022	—	7,600.1	—	—	—	—	—	—	4.75×	257.9	255.1	-1.65%	0
FY 2021 Q4	Dec 31, 2021	—	6,795	—	—	—	—	—	—	4.46×	257	254.61	-2.09%	368.18
FY 2021 Q3	Sep 30, 2021	—	6,275.7	—	—	—	—	—	—	4.62×	259.71	257.88	-0.97%	632.27
FY 2021 Q2	Jun 30, 2021	—	6,063.68	—	—	—	—	—	—	4.61×	261.02	258.99	-0.25%	0
FY 2021 Q1	Mar 31, 2021	—	6,304.33	—	—	—	—	—	—	4.39×	261.92	259.37	-0.17%	424.95
FY 2020 Q4	Dec 31, 2020	—	5,988.19	—	—	—	—	—	49.12×	4.33×	263.11	260.04	0.79%	131.1
FY 2020 Q3	Sep 30, 2020	—	5,358.09	—	—	—	—	—	47.44×	3.72×	264.08	260.39	1.34%	108.01
FY 2020 Q2	Jun 30, 2020	—	4,831.33	—	—	—	—	—	36.78×	3.72×	263.4	259.64	1.36%	0
FY 2020 Q1	Mar 31, 2020	—	3,593.41	—	—	—	—	—	28.41×	3.54×	263.52	259.82	1.61%	300.03
FY 2019 Q4	Dec 31, 2019	—	3,109.32	—	—	—	—	—	20.47×	3.61×	262.11	258	1.23%	36.06
FY 2019 Q3	Sep 30, 2019	—	3,397.94	—	—	—	—	—	12.28×	3.44×	260.47	256.95	0.8%	0.1
FY 2019 Q2	Jun 30, 2019	—	3,294.68	—	—	—	—	—	13.11×	3.74×	259.82	256.15	0.79%	56.01
FY 2019 Q1	Mar 31, 2019	—	2,893.89	—	—	—	—	—	11.11×	3.78×	260.18	255.7	0.97%	99.84
FY 2018 Q4	Dec 31, 2018	—	2,650.13	—	—	—	—	—	8.76×	3.43×	259.81	254.87	1.32%	143.01
FY 2018 Q3	Sep 30, 2018	—	2,478.3	—	—	—	—	—	—	3.71×	259.79	254.91	1.85%	92.01
FY 2018 Q2	Jun 30, 2018	—	2,145.36	—	—	—	—	—	—	3.67×	258.58	254.14	2.67%	105.03
FY 2018 Q1	Mar 31, 2018	—	1,995.89	—	—	—	—	—	—	3.68×	258.53	253.23	2.93%	10
FY 2017 Q4	Dec 31, 2017	—	1,665.41	—	—	—	—	—	1.78×	3.28×	256.8	251.56	2.49%	0
FY 2017 Q3	Sep 30, 2017	—	1,384.97	—	—	—	—	—	—	3.28×	250.27	250.27	2.18%	0
FY 2017 Q2	Jun 30, 2017	—	1,223.13	—	—	—	—	—	—	3.49×	251.64	247.52	1.24%	0
FY 2017 Q1	Mar 31, 2017	—	1,003.68	—	—	—	—	—	—	3.82×	248.7	246.02	0.9%	0
FY 2016 Q4	Dec 31, 2016	—	1,183.95	—	—	—	—	—	—	2.31×	247.76	245.45	1.02%	—
FY 2016 Q3	Sep 30, 2016	—	719.69	—	—	—	—	—	—	2.08×	244.92	244.92	1.22%	—
FY 2016 Q2	Jun 30, 2016	—	605.87	—	—	—	—	—	—	2.33×	244.48	244.48	1.55%	—
FY 2016 Q1	Mar 31, 2016	—	604.25	—	—	—	—	—	—	2.54×	243.83	243.83	1.81%	—
FY 2015 Q4	Dec 31, 2015	—	714.77	—	—	—	—	—	—	2.78×	242.98	242.98	1.85%	—
FY 2015 Q3	Sep 30, 2015	—	756.25	—	—	—	—	—	—	3.63×	241.97	241.97	2.47%	—
FY 2015 Q2	Jun 30, 2015	—	870.54	—	—	—	—	—	—	3.46×	240.76	240.76	2.97%	—
FY 2015 Q1	Mar 31, 2015	—	664.88	—	—	—	—	—	—	4.49×	239.49	239.49	2.84%	—
FY 2014 Q4	Dec 31, 2014	—	625.26	—	—	—	—	—	—	4.2×	238.57	238.57	3.16%	—
FY 2014 Q3	Sep 30, 2014	—	718.56	—	—	—	—	—	—	4.43×	236.14	236.14	2.44%	—
FY 2014 Q2	Jun 30, 2014	—	420.56	—	—	—	—	—	—	3.71×	233.81	233.81	5.29%	—
FY 2014 Q1	Mar 31, 2014	—	424.05	—	—	—	—	—	—	3.83×	232.89	232.89	8.11%	—
FY 2013 Q4	Dec 31, 2013	—	569.3	—	—	—	—	—	—	3.99×	235.72	231.26	7.76%	—
FY 2013 Q3	Sep 30, 2013	—	583.18	—	—	—	—	—	—	4.03×	230.51	230.51	7.83%	—
FY 2013 Q2	Jun 30, 2013	—	531.25	—	—	—	—	—	—	4.5×	222.05	222.05	5.07%	—
FY 2013 Q1	Mar 31, 2013	—	379.1	—	—	—	—	—	—	3.84×	215.42	215.42	3.56%	—
FY 2012 Q4	Dec 31, 2012	—	489.41	—	—	—	—	—	0.14×	3.67×	214.61	214.61	3.8%	—
FY 2012 Q3	Sep 30, 2012	—	436.89	—	—	—	—	—	12.01×	4.02×	213.77	213.77	3.77%	—
FY 2012 Q2	Jun 30, 2012	—	454.06	—	—	—	—	—	18.73×	4.2×	211.34	211.34	3.39%	—
FY 2012 Q1	Mar 31, 2012	—	267.92	—	—	—	—	—	11.96×	4.02×	219.26	208.02	2.81%	—
FY 2011 Q4	Dec 31, 2011	—	475.32	—	—	—	—	—	2.96×	3.39×	217.6	206.76	2.68%	—
FY 2011 Q3	Sep 30, 2011	105	542.55	-437.54	0.15×	5.02%	—	—	-8.21×	2.27×	219.35	206	2.55%	—
FY 2011 Q2	Jun 30, 2011	105	458.2	-353.2	0.25×	5.96%	—	—	-22.61×	1.73×	204.41	204.41	2%	—
FY 2011 Q1	Mar 31, 2011	105	446.54	-341.54	0.27×	6.82%	—	—	-25.46×	2.1×	202.33	202.33	1.71%	—
FY 2010 Q4	Dec 31, 2010	—	243.2	—	—	—	—	—	-36.11×	2.23×	201.36	201.36	—	—
FY 2010 Q3	Sep 30, 2010	—	569.9	—	—	—	—	—	—	3.94×	200.89	200.89	—	—
FY 2010 Q2	Jun 30, 2010	—	337.61	—	—	—	—	—	—	3.44×	200.4	200.4	—	—
FY 2010 Q1	Mar 31, 2010	—	396.55	—	—	—	—	—	—	5.33×	198.94	198.94	—	—

Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Debt uses reported borrowings, with overlapping concepts treated as alternatives. Cash excludes restricted cash and short-term investments. Dilution compares split-normalized weighted average basic shares year over year. Share buyback spending does not by itself measure shares retired.

Market prices: Yahoo Finance · VRTX, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Total debt: Reported borrowing balances. Uses an aggregate including current maturities, or current plus noncurrent debt. Adds separately disclosed short-term borrowings, with commercial paper as a fallback, unless the selected current/aggregate concept already includes them. Finance leases are included when part of the reported debt concept; undisclosed components are not estimated.
Cash & equivalents: Unrestricted reported cash and cash equivalents. Excludes short-term investments and restricted cash.
Net debt: Total debt − cash and equivalents. Negative means net cash.
Debt / equity: Total debt / equity including noncontrolling interests. Nonpositive equity yields unavailable.
Debt / assets: Total debt / total assets × 100.
Net debt / EBITDA: Period-end net debt / (TTM operating income + TTM depreciation and amortization). Negative net debt is retained.
Debt / FCF: Period-end reported debt / positive TTM free cash flow. Reflects the selected reported capex scope and SBC option.
Interest coverage: TTM operating income / positive TTM interest expense. IFRS finance costs can include more than interest.
Current ratio: Current assets / positive current liabilities.
Diluted shares: Reported weighted average diluted shares, normalized for subsequent recorded stock splits. Fourth-quarter counts use a day-weighted annual/nine-month reconstruction where possible.
Basic shares: Reported weighted average basic shares, normalized for subsequent recorded stock splits.
Share count growth: Year-over-year change in split-normalized weighted average basic shares × 100. A dilution proxy; negative means a lower share count.
Share repurchases: Reported cash payments for repurchase of common shares. This is spending, not a buyback yield.